Author:
Qin Bowen,Li Yueqiang,Kuang Dong,Yang Xi,Pan Chunyu,Cai Xiaojing,Li Junhua
Abstract
Abstract
Background
Membranous nephropathy (MN) is a common type of nephrotic syndrome (NS) in adults, accounting for about 20–30% of cases. Although secondary to specific factors, the coexistence of MN and mantle cell lymphoma (MCL) has been scarcely reported in clinical literature.
Case presentation
A 59-year-old Chinese male was admitted to the hospital with a generalized pruritic rash with bilateral lower extremity edema, which did not improve significantly after symptomatic treatment. He had undergone renal biopsy, and the diagnosis was thought to be secondary MN (SMN), therefore, we did a lymph node biopsy on the patient and found that MN was complicated with MCL. Soon after, the patient was admitted to the hematology department for a BR chemotherapy regimen (composed of bendamustine 90 mg/m2 BSA (body surface area), rituximab 375 mg/m2 BSA and dexamethasone 5 mg), and during the post-treatment follow-up, both his symptoms and renal function improved.
Conclusions
The mechanism underlying the combination of SMN and MCL remains elusive and exceedingly rare, consequently often overlooked in clinical practice. This case serves to offer valuable clinical insights for diagnosis and treatment, while emphasizing the pivotal role of renal pathology in clinical assessment.
Publisher
Springer Science and Business Media LLC
Reference13 articles.
1. Geropoulos G, Psarras K, Vlachaki E, Kakos C, Vetsiou E, Vamvakis K, Sousos N, Mpouras V, Symeonidis N, Pavlidis ET, et al. Cutaneous manifestations of mantle cell lymphoma: an extensive literature review. Acta Dermatovenerol Alp Pannonica Adriat. 2020;29(4):185–91.
2. Ishiwatari A, Hasegawa J, Hoshino Y, Kaga T, Abe Y, Wakai S. Simultaneous nephrotic syndrome and hepatitis in secondary syphilis: case report and review of the literature. CEN Case Rep. 2015;4(2):223–7.
3. Kumar A, Eyre TA, Lewis KL, Thompson MC, Cheah CY. New directions for Mantle Cell Lymphoma in 2022. Am Soc Clin Oncol Educ Book. 2022;42:1–15.
4. Hanel W, Epperla N. Emerging therapies in mantle cell lymphoma. J Hematol Oncol. 2020;13(1):79.
5. Andeen NK, Abdulameer S, Charu V, Zuckerman JE, Troxell M, Kambham N, Alpers CE, Najafian B, Nicosia RF, Smith KD, et al. A diverse spectrum of immune complex- and complement-mediated kidney diseases is associated with mantle cell lymphoma. Kidney Int Rep. 2022;7(3):568–79.